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Abstract
Introduction: Sjögren’s syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and
lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that TH17
cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive
inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of TH17
activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS.
Methods: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or
LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and
IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to
quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA)
staining, and stimulated saliva flow rates were used to profile SjS disease severity.
Results: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited
long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice
injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed
that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF,
lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva
flow rates.
Conclusions: These data support the concept that IL-27, when provided exogenously, can induce a suppressive
effect on SjS development and thus may be an effective therapeutic agent for regulating TH17 pro-inflammatory
activity in autoimmune diseases where the TH17 system has been shown to play an important role in their
pathogenesis.
Introduction
Interleukin 27 (IL-27), along with IL-12, IL-23, and IL-35,
is a novel cytokine of the IL-6/IL-12 family. It is com-
posed of two subunits: IL-12p40-related Epstein-Barr
virus-induced gene 3 (Ebi3) protein and IL-12p35-related
p28 protein (p28) [1]. The orphan cytokine receptor
WSX-1 (TCCR) and glycoprotein-130 (gp130) make up
the heterodimeric signal transducing receptor for IL-27
[2]. IL-27 acts on CD4+ T cells and plays a pivotal role as
both a pro- and anti-inflammatory cytokine. As a pro-
inflammatory cytokine, IL-27 activates T helper 1 (TH1)
responses in the early phases of immunity, in which
secretion of interferon-gamma (IFN-g) is one of the key
inflammatory mediators in autoimmunity. The mechan-
ism appears to be the activation of signal transducer and
activator of transcription 1 (STAT1) [3]. As an anti-
inflammatory protein, IL-27 suppresses IL-2, antagoniz-
ing IL-6 function and activating expression of suppressor
of cytokine signaling (SOCS) protein(s) [4]. In studies
with WSX-/- receptor knockout mice, abnormal signal
transduction of IL-27 showed hyper-production of var-
ious pro-inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-a) and IL-6 when challenged by
Trypanosoma cruzi or T. gondii [5,6]. Moreover, IL-27
can suppress the expression of forkhead box P3-positive
(Foxp3+) regulatory T (Treg) cells and act as a negative
regulator of human neutrophil function [7,8]. Recent
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studies also confirmed that IL-27 has anti-tumor effects
[7,9].
IL-27 is well known for its inhibitory effects on retinoic
acid-related orphan receptor gamma t (RORgt), the tran-
scription factor for TH17 cells, by activating both T-bet,
the transcription factor for TH1 cells, and the STAT1
pathway, thus inhibiting expression of IL-17A (commonly
referred to as IL-17) [10]. In addition, WSX-1-deficient
mice showed greater susceptibility for experimental auto-
immune encephalomyelitis (EAE) in comparison with
wild-type control mice and exhibited increased levels of
IL-17 [11]. More recent reports have described the capa-
city of IL-27 to suppress TH17 cells by inhibiting TH17
cell differentiation, thereby reducing severity of TH17-
mediated autoimmune diseases [11,12].
Gene delivery using recombinant adeno-associated virus
(rAAV)-based vectors has been shown to convey long-
term gene expressions in treated hosts [13-16]. Previous
studies of gene therapy using AAV have also proven its
safety and ability to elicit minimal inflammatory responses
in comparison with other types of gene delivery agents
[17-20]. Nevertheless, to date, no study using the rAAV
system has reported a role for IL-27 in Sjögren’s syndrome
(SjS). Thus, we examined the effects of IL-27 treatment on
SjS disease of C57BL/6.NOD-Aec1Aec2 mice when deliv-
ered either at 6 weeks of age (pre-disease) or at14 weeks
of age (clinical disease). Results reported here indicate that
IL-27, a potent inhibitor of TH17 cell development, may
be a useful reagent for treating SjS.
Materials and methods
Animals
C57BL/6.NOD-Aec1Aec2 mice were bred and maintained
under specific pathogen-free conditions in the animal
facility of Animal Care Services at the University of Florida
(Gainesville, FL, USA). Development of the C57BL/6.
NOD-Aec1Aec2 mouse and its SjS-like disease phenotype
is described elsewhere [21]. Briefly, C57BL/6.NOD-
Aec1Aec2 mouse was developed by introducing two
genetic regions, one on chromosome 1 (designated Aec2)
and the second on chromosome 3 (designated Aec1),
derived from the NOD/LtJ mouse, into the SjS-non-sus-
ceptible C57BL/6J mouse. All animals were maintained on
a 12-hour light-dark schedule and provided food and acid-
ified water ad libitum. At times indicated in the article,
mice were euthanized by cervical dislocation after deep
anesthetization with isoflurane, and their organs and tis-
sues were freshly harvested for analyses. All experiments
and analyses described in this article were performed with
male and female mice. The breeding and the use of
C57BL/6.NOD-Aec1Aec2 mice for gene therapy study as
described here were approved by the University of Flori-
da’s Institutional Animal Care and Use Committee and
Institution Biosafety Committee.
Recombinant AAV2-IL27 (rAAV2-IL27) vector construction
The serotype 2 adeno-associated viral vector (AAV2)
was designed to contain a cytomegalovirus (CMV)/
chicken-b-actin hybrid promoter, an internal ribosome
entry site (IRES), and the inverted terminal repeat
sequences (pTR-UF14) (Figure S1A of Additional file 1).
To fully recapitulate the functionality of mouse IL-27
cytokine, a rAAV2-IL27 vector was constructed by
inserting the genes encoding the two subunits of IL-27
(Ebi3 and p28) into a pTR-UF14 vector. Ebi3 and p28
were generated by polymerase chain reaction (PCR)
from murine cDNA by using two pairs of primers (Ebi3:
forward 5’-AAACTAGTAGGTCCTTCCCTGGGGC-
CAGGT-3’ and reverse 5’-TTTGATATCAAGGATC-
CAGTCCCTCTTCAG-3’ and p28: forward 5’-AAAAA
GCGGCCGCATGGGCCAGGTGACA GGA-3’ and
reverse 5’-TTTGTCGACTTAGGAATCCCAGGCT-
GAGCC-3’). Ebi3 and p28 subunits flanked by IRES
component were constructed allowing the co-expression
of IL-27 subunits driven by the same promoter (Figure
S1B of Additional file 1). We used AAV2 vector encod-
ing beta galactosidase (rAAV2-LacZ) as an AAV2 con-
trol vector, whose construction was previously reported
[22].
Functional activity of IL-27 expressed from the rAAV2-
IL27 vector
rAAV2-IL27 and its backbone (pTR-UF14) plasmids
were transfected separately into HEK 293 cells by using
TransIT-293 Transfection Reagent (Mirus Bio LLC,
Madison, WI, USA) in accordance with the instructions
of the manufacturer. After transfection, cell pellet and
culture media were collected at different time points up
to 48 hours, and expression of the two subunits of IL-27
was measured. Ebi3 was determined by Western blotting
by using anti-mouse Ebi3 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and p28 was detected by
enzyme-linked immunosorbent assay (ELISA) by using a
Quantikine kit for mouse IL-27 p28 (R&D Systems,
Minneapolis, MN, USA). Biological activity was deter-
mined by flow cytometry. Culture supernatants from
rAAV2-IL27 or empty AAV2-transfected HEK293 cells
were collected (mock). C57BL/6J splenocytes were incu-
bated with mock, IL-6/transforming growth factor-beta
(IL-6/TGF-b) for optimal TH17 differentiation, and IL-
6/TGF-b with supernatants of AAV2-IL27 transfected
cells at 37°C for 5 days. IL-17+ cells were measured by
flow cytometry.
Packaging of recombinant AAV2 (rAAV2) vector particles
To generate rAAV2 viral particles, adenoviral helper
packaging plasmid pDG was used. Plates (15 cm) with less
than 40% confluent HEK 293T cells were co-transfected
with either pAAV2-LacZ (control vector) or rAAV2-IL27
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in accordance with standardized methods [23]. Clarified
cell lysates were adjusted to a refractive index of 1.372 by
the addition of CsCl and centrifuged at 38,000 revolutions
per minute (rpm) for 65 hours at 20°C. Equilibrium den-
sity gradients were fractionated, and fractions with a
refractive index of 1.369 to 1.375 were collected. The par-
ticle titer was quantified by real-time PCR, and the vector
was stored at -80°C.
Injections of vectors
Two different age groups of C57BL/6.NOD-Aec1Aec2
mice were used to take advantage of the pre-disease and
clinical disease stages of the animal [24] for the IL-27
gene therapy, thereby aiming to either prevent the onset
of the disease or reverse the disease phenotype of SjS
(6-week-old mice for pre-disease stage and 14-week-old
mice for clinical disease stage, respectively). Mice were
treated systemically with saline or rAAV2-LacZ or
rAAV2-IL27, and there were 10 mice (five male and five
female) per treatment for each disease stage. Systemic
delivery was done via intravenous injection in tail veins.
Mice were anesthetized with a ketamine (100 mg/mL,
1 mL/kg body weight; Fort Dodge Animal Health, Fort
Dodge, IA, USA) and xylazine (20 mg/mL, 0.7 mL/kg
body weight; Phoenix Scientific, St. Joseph, MO, USA)
cocktail by intraperitoneal injection. Then 50 μL of vec-
tor solution containing 2 × 1010 vector genome (VG)
was injected. Control groups received either the same
amount of rAAV2-LacZ VG or the same volume of sal-
ine. The dosage was chosen on the basis of published
studies by others for extensive study of dosage optimiza-
tion [25-29]. All animals were sacrificed at 20 weeks
after delivery. At the time of euthanization, systemic
transgene expression was determined by using quantita-
tive real-time PCR (Figure S2 of Additional file 2).
Intracellular cytokine staining and flow cytometry analysis
Single-cell suspensions of spleen cells were prepared
from C57BL/6.NOD-Aec1Aec2 mice as described else-
where [30] and at the ages designated in the text. In
brief, spleens were freshly explanted, gently minced
through stainless steel sieves, suspended in phosphate-
buffered saline (PBS), and centrifuged (1,200 rpm for
5 minutes). Erythrocytes were lysed by a 7-minute incu-
bation in 0.84% NH4Cl. The resulting leukocyte suspen-
sions were washed two times in PBS, counted, and
re-suspended in culture media (RPMI 1640 medium,
10% fetal bovine serum, 2 mM L-glutamine, and
0.05 mM b-mercaptoethanol) to a density of 2 × 106
cells/mL. One million cells were pipetted to individual
wells of a 24-well microtiter plate pre-coated with anti-
CD3 (10 μg/mL; BD Pharmingen, San Diego, CA, USA)
and anti-CD28 (2 μg/mL; BD Pharmingen) antibodies
for T-cell activation. Cells were incubated for 5 hours
with Leukocyte Activation Cocktail containing GolgiPlug
(2 μL/mL; BD Pharmingen). Collected cells were fixed
and permeabilized by using a Cytofix/CytopermFixation/
Permeabilization kit (BD Pharmingen). The flow cyto-
metry acquisition for intra- and extra-cellular staining
was performed following staining with fluorescein iso-
thiocyanate (FITC)-conjugated anti-mouse IL-27 (R&D
Systems), phycoerythrin (PE)-conjugated anti-IL-17
(eBioscience, San Diego, CA, USA), and PE-Cy7-conju-
gated anti-mouse CD4 (Invitrogen, Carlsbad, CA, USA)
for the detection of cytokines from gene-delivered mice.
The cells were counted by using a BD ACCURI C6
Flow Cytometer (BD Biosciences, San Jose, CA, USA)
and analyzed by FlowJo software (TreeStar Inc., Ash-
land, OR, USA). CD3+ and CD4+ T cells were gated,
and the cells were analyzed for IL-27+ or IL-17+ cells.
Cytokine level of peripheral blood
Measurement of IL-27levels in sera samples was con-
ducted by using a Quantikine kit for mouse IL-27 p28
(R&D Systems). IL-17, and IL-10 levels are detected using
mouse IL-17 and IL-10 ELISA kits (Life Technologies,
Grand Island, NY, USA). All procedures were performed
in accordance with the instructions of the manufacturers.
Readings were carried out by using a Model 680 Micro-
plate Reader (Bio-Rad, Hercules, CA, USA).
Hematoxylin and eosin staining and histological
assessment
Salivary glands, lacrimal glands, liver, lung, and kidney
were surgically removed from each C57BL/6.NOD-
Aec1Aec2 mouse at the time of euthanasia and placed
in 10% phosphate-buffered formalin for 24 hours. Fixed
tissues were embedded in paraffin and sectioned at a
thickness of 5 μm. Paraffin-embedded sections were
deparaffinized by immersing in xylene, followed by
dehydration in ethanol. The prepared tissue sections
were stained with hematoxylin and eosin (H&E) dye
(Histology Tech Services, Gainesville, FL, USA). H&E-
stained sections were observed under a microscope for
glandular structure and leukocyte infiltration. Lympho-
cytic foci (LF) were enumerated by three individuals in
blinded fashion. LF were defined as aggregates of more
than 50 leukocytes quantified per each histological sec-
tion, and adjacent sections were used for immunofluor-
escent staining. Stained sections were observed at ×6
magnification by using a Leica MZ8 microscope, and
images were obtained with Leica application suite (ver-
sion 2.4.0.R1; Leica, Wetzlar, Germany).
Immunofluorescence staining
Tissue sections were deparaffinized, rehydrated, and
blocked with hydrogen peroxide. For antigen retrieval,
tissue sections were heated to 100°C under pressure with
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10 mM citrate buffer for 15 minutes. The sections were
incubated with rat anti-mouse B220 (BD Pharmingen,
San Diego, CA, USA) or goat anti-mouse CD3 (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA) to detect
B cells and T cells, respectively, overnight at 4°C. The
sections were washed two times with PBS-Tween and
incubated with Texas Red-conjugated rabbit anti-rat IgG
(Biomeda, Foster City, CA, USA) for B220 marker and
FITC-conjugated rabbit anti-goat IgG (Sigma-Aldrich, St.
Louis, MO, USA) for CD3 detection for 30 minutes at
room temperature. After additional washes, the slides
were treated with mounting medium with 4’-6-diami-
dino-2-phenylindole (DAPI) (Vector Laboratories,
Burlingame, CA, USA). Stained sections were observed at
×100 magnification with a Zeiss Axiovert 200 M micro-
scope, and images were obtained with AxioVs40 software
(version 4.7.1.0; Carl Zeiss, Jena, Germany).
Detection of anti-nuclear antibodies in the sera
Anti-nuclear antibodies (ANAs) in the sera of mice were
detected by using an HEp-2 ANA kit (Inova Diagnostics,
Inc., San Diego, CA, USA). All procedures were performed
in accordance with the instructions of the manufacturer.
In brief, HEp-2-fixed substrate slides were overlaid with
appropriate mouse sera diluted 1:50, 1:100, 1:200, 1:400,
and 1:800. Slides were incubated for 1 hour at room tem-
perature in a humidified chamber. After three washes for
5 minutes with PBS, the substrate slides were covered with
Alexa 488-conjugated goat anti-mouse IgG (H/L) (Invitro-
gen) diluted 1:100 for 45 minutes at room temperature.
After three washes, fluorescence was detected by fluores-
cence microscopy at ×200 magnification by using a Zeiss
Axiovert 200 M microscope, and all images were obtained
with AxioVs40 software (version 4.7.1.0; Carl Zeiss) with a
constant exposure of 0.3 seconds (Carl Zeiss). In this
study, three individuals in blinded fashion examined posi-
tive staining patterns.
Measurement of stimulated saliva flow
To measure stimulated saliva flow, each mouse was
weighed and injected with a cocktail of isoproterenol
(0.2 mg/mL) and pilocarpine (0.5 mg/mL) in 100 μL of
saline by intraperitoneal injection. Saliva was collected for
10 minutes from the oral cavity of individual mice by
using a micropipette starting 1 minute after injection of
the secretagogue. The volume of each saliva sample was
measured. Baseline saliva flow rates (SFRs) were measured
a week before the gene therapy, and SFRs were measured
every 4 weeks after 8 weeks of post-gene delivery periods
until the end of the experiment in each group.
Statistical analyses
The data are expressed as the mean ± standard error of
the mean. Statistical evaluation was determined by using
one-way analysis of variance test with the GraphPad
Prism software (GraphPad Software, Inc., La Jolla, CA,
USA) or chi-squared test. A P value of less than 0.05
considered statistically significant.
Results
rAAV2-IL27 plasmid is highly efficient in producing a
functional IL-27 product in vitro
To determine functional activity of the rAAV2-IL27 plas-
mid construct, HEK293 cells were transfected with either
the rAAV2-IL27 or its backbone, pTR-UF14 plasmid. To
control for background, untreated HEK293 cells were cul-
tured in medium containing the transfection reagents only
(representing a mock transfection). Forty-eight hours after
transfection, cell lysates were prepared and culture media
were collected to quantify expression levels by ELISA of
both secreted and non-secreted IL-27 protein. As pre-
sented in Figure 1A, IL-27 p28 levels were significantly
increased in lysates from cells transfected with rAAV2-
IL27 (222 pg/mL) in comparison with lysates from either
the mock transfected (24 pg/mL) or pTR-UF14 transfected
(22 pg/mL) cells. Similarly, examination of culture media
showed elevated levels of IL-27 p28 (272 pg/mL), but IL-
27 p28 was not detected in either culture media of mock
transfected or pTR-UF14 transfected HEK293 cells. Analy-
sis of the cell lysates and culture media also indicated that
Ebi3 expression was highly increased in rAAV2-IL27
transfected cells (data not shown).
Biological activity of recombinant IL-27 (rIL-27)
secreted by rAAV2-IL27 was determined by using culture
media supernatants collected from the rAAV2-IL27 and
control by supernatants from pTR-UF14 transfected
HEK293 cells or cells alone. C57BL/6J splenocytes cul-
tured in media containing IL-6 and TGF-b supplemented
with supernatants containing rIL-27 showed significant
decreases in IL-17+ cells with concomitant increases in
IFN-g+ cells in comparison with media supplemented with
supernatant from either pTR-UF14 or mock transfected
cells (Figure 1B). Considered together, these results indi-
cate that the heterodimeric rIL-27 protein is properly
expressed by the rAAV2-IL27 vector and is biologically
functional in suppressing TH17 cells in vitro.
Decreased serum IL-17 levels in mice following rAAV2-
IL27 treatment
To determine the systemic cytokine levels of IL-27 in
C57BL/6.NOD-Aec1Aec2 mice following treatment with
rAAV2-IL27, rAAV2-LacZ (vector control), or saline
(negative control), sera of treated mice were examined
8, 12, and 20 weeks after gene delivery. As indicated in
Figure 2A, 6-week-old mice inoculated with rAAV2-
IL27 exhibited significant increases in IL-27 levels
during the subsequent 20-week observation period,
resulting in a threefold increase in comparison with the
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rAAV2-LacZ- or saline-treated control groups (91 ver-
sus 34 and 30 pg/mL, respectively). High levels of circu-
lating IL-27 were concomitantly correlated with IL-17
level decreases observed at both 12 and 20 weeks after
injection (Figure 2C). Interestingly, IL-10 levels were
unaffected by the increased levels of IL-27 (Figure 2E).
Similar, yet more pronounced, results were observed
in mice administered rAAV2-IL27 at 14 weeks of age,
the time of adaptive immunity onset in the C57BL/6.
NOD-Aec1Aec2 mice. At 8 weeks after injection, mice
injected with rAAV2-IL27 showed dramatic increases in
the levels of IL-27 in comparison with the rAAV2-LacZ-
or saline-treated control groups (278 versus 175 and 173
pg/mL, respectively), and these levels were maintained
for at least 20 weeks after injection (Figure 2B).
Concomitantly, rAAV2-IL27-treated mice showed
reduced levels of IL-17 at both 12 and 20 weeks after
vector delivery in comparison with the rAAV2-LacZ-
and saline-treated control groups (Figure 2D), indicating
that decreased expression of IL-17 in the sera is corre-
lated with the increased expression of IL-27 in the
rAAV2-IL27-treated mice. In contrast to mice treated at
6 weeks of age, IL-10 was highly elevated at 8 weeks
after injection in mice treated with rAAV2-IL27 in the
clinical disease phase (Figure 2F). These data suggest a
direct negative regulation of TH17 cells with a corre-
sponding upregulation of IL-10 production, which could
further inhibit cytokine productions from TH1, TH2, and
TH17 cells. Thus, the two disease stages of SjS respond
differently to IL-27 treatment.
Figure 1 Generation of functional IL-27-expressing vector (rAAV2-IL27). (A) IL-27 p28 expression levels in the cell lysates or culture media
of mock transfection which contain transfection reagents only (white bar) or control empty AAV2 plasmid (grey bar) or rAAV2-IL27 (black bar)
transfected HEK293 cells at 48 hours after transfection. (B) Biological effects of IL-27 were generated from rAAV2-IL27 on C57BL/6 splenocytes by
using media only or (a) mock, (b) IL-17 differentiation cocktail containing IL-6 and transforming growth factor-beta, or (c) IL-17 differentiation
cocktail with supernatant IL-27 from rAAV2-IL27 transfected HEK293 cells (sIL-27). The experiment was done in triplicate and repeated three times
for consistency. Values in bar graphs are mean. **P < 0.01, rAAV2-IL27 group versus mock or rAAV2 transfected by one-way analysis-of-variance
test. IFN-g, interferon-gamma; IL, interleukin.
Lee et al. Arthritis Research & Therapy 2012, 14:R172
http://arthritis-research.com/content/14/4/R172
Page 5 of 14
Figure 2 Changes in circulating cytokines in sera following rAAV2-IL27 treatment. Ten mice (five male and five female) were treated
systemically with saline (negative control) or rAAV2-LacZ (vector control) or rAAV2-IL27 per treatment for each disease stage (6-week-old mice
for pre-disease stage and 14-week-old mice for clinical disease stage). Each mouse was injected with 2 × 1010 vector genome of rAAV2-IL27 or
rAAV2-LacZ in 50 μL of saline via intravenous line in tail veins. Sera were collected 1 week before (-1, baseline) and 8, 12, and 20 weeks after the
treatment of pre-disease and clinical disease mice groups. Levels of cytokines (IL-27, IL-17, and IL-10) were detected by enzyme-linked
immunosorbent assay. IL-27 levels in pre-disease (A) and clinical-disease (B) stages. IL-17 levels in pre-disease (C) and clinical-disease (D) stages.
IL-10 levels in pre-disease (E) and clinical-disease (F) stages. Values are mean ± standard error of the mean (n = 7). *P < 0.05 rAAV2-IL27 group
versus rAAV2-LacZ or saline groups by one-way analysis-of-variance test; **P < 0.01. IL, interleukin; IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-
LacZ-treated groups; Saline, saline-treated groups.
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Intravenous injection of rAAV2-IL27 negatively regulates
splenic TH17 cell functions
As mentioned previously, IL-27 functions to inhibit the
activity of TH17 cells by negatively regulating the produc-
tion of IL-17 while directly promoting the production of
IFN-g by TH1 cells. Since rAAV2-IL27 was administered
intravenously, splenocytes were isolated to examine the
systemic effects of the vector on TH17 and TH1 cells.
Splenocytes from mice treated at either 6 or 14 weeks of
age were isolated 20 weeks after treatment to profile the
levels of IL-27, IFN-g, and IL-17 produced by specific
T-cell populations. As presented in Figure 3, rAAV2-
IL27-injected mice showed relative increases in the num-
ber of CD3+CD4+IL-27+ cells, determined by flow cyto-
metry analyses, in comparison with mice treated with
rAAV2-LacZ vector or saline. The increases in IL-27+
T cells were associated with increases in IFN-g+ cells.
Although rAAV2-IL27 treatment of mice at 6 weeks of
age resulted in increased numbers of IL-27+ T cells, there
were no differences in IL-17+ T cells between saline-,
rAAV2-LacZ-, and rAAV2-IL27-treated groups, and this
was possibly due to the overall low numbers of IL-27+
T cells. In contrast, mice injected with rAAV2-IL27 at 14
weeks of age had decreased numbers of IL-17+ T cells
with a concomitant two- to fourfold increase in IL-27+
T cells over rAAV2-LacZ- and saline-treated groups
(Figure 3). These data are consistent with the concept
that systemic delivery of IL-27 can regulate the levels of
IL-17+ T cells in the spleen, but high levels of exogenous
IL-27 may needed to suppress the levels of IL-17.
Lymphocytic infiltrates in the exocrine glands of
rAAV2-IL27-injected mice
Lymphocytic infiltration present in the salivary glands is
one of the main diagnostic markers for SjS. In the
C57BL/6.NOD-Aec1Aec2 mouse model, the development
and onset of autoimmunity in the exocrine glands are
considered the results of acinar cell apoptosis that signals
an influx of leukocytes expressing pro-inflammatory
cytokines. Salivary gland lymphocytic infiltrates initially
are composed of T-cell clusters followed by recruitment
of B lymphocytes [31,32]. The migration of specific
T-cell populations secreting IL-17 and IL-23 has been
shown to directly contribute to the pathogenesis of the
disease [33]. Therefore, to determine the effect of
rAAV2-IL27 treatment on lymphocytic infiltration in the
salivary glands of mice injected at 6 or 14 weeks of age
with rAAV2-IL27, freshly explanted, formalin-fixed, par-
affin-embedded salivary gland sections were examined
after euthanizaton at 20 weeks after treatment.
Representative images of salivary gland infiltrates,
shown in Figure 4, reveal the presence of LF composed
of both B and T lymphocytes, whereas the numbers of LF
in the salivary glands were scored for each experimental
group (Table 1). As can be seen, rAAV2-IL27-treated
mice showed no significant reductions in the number of
Figure 3 rAAV2-IL27-expressing vector is capable of negatively regulating splenic TH17 cells. Splenocytes were isolated from each mouse
and stained for CD3 and CD4 fluorochrome-conjugated antibodies. Cells were further intracellularly stained for IL-27, IL-17, and IFN-g. Flow
cytometry analysis was performed with cells gated on CD4+ populations. Values are mean ± standard error of the mean (n = 7). *P < 0.05
rAAV2-IL27 group versus rAAV2-LacZ or saline groups by one-way analysis-of-variance test; **P < 0.01. IFN-g, interferon-gamma; IL, interleukin; IL-
27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; Saline, saline-treated groups.
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LF in the salivary glands in comparison with either
rAAV2-LacZ- or saline-treated mice, irrespectively of the
age at which treatment of the mice was carried out. In
contrast, lacrimal glands of the rAAV2-IL27-treated mice
were noted to have a decrease in the numbers of LF in
comparison with saline-treated mice, whereas lacrimal
glands explanted from mice treated with rAAV2-LacZ
showed slightly lower LF scores. Furthermore, in general,
larger infiltrates were found in the rAAV2-LacZ- and sal-
ine-treated groups with higher numbers of B cells in
comparison with rAAV2-IL27-treated mice. Owing to
the intravenous injection of the viral vectors, other
Figure 4 Lymphocytic infiltrates in the salivary glands. Representative images for hematoxylin and eosin (H&E) and CD3/B220 staining for
saline-, rAAV2-LacZ-, and rAAV2-IL27-treated groups at 20 weeks after gene delivery in pre-disease and clinical disease groups. H&E images were
taken at ×6 magnification and immunofluorescence staining images of lymphocytic infiltrates with anti-CD3 to detect T cells (green) and anti-
B220 to detect B cells (red) were taken at ×100 magnification with a Zeiss Axiovert 200 M microscope. IL-27, rAAV2-IL27-treated groups; LacZ,
rAAV2-LacZ-treated groups; Saline, saline-treated groups.
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organs such as liver, lungs, and kidney were also exam-
ined for lymphocytic infiltration. However, no significant
pathological changes were observed between mice
belonging to the different treatment groups (data not
shown). These results indicate that systemic injection of
rAAV2-IL27 has a positive impact on LF scores in the
lacrimal glands, especially when treatment is initiated at
6 weeks of age, but appears to have little or no impact on
LF scores in salivary glands.
Intravenous injection of rAAV2-IL-27 treatment alters the
anti-nuclear antibody profile in C57BL/6.NOD-Aec1Aec2
mice
Patients with SjS often develop ANAs, specifically anti-
Ro (SS-A) or anti-La (SS-B) or both. ANAs that gener-
ally show a specked staining pattern when HEp-2 cells
are used are highly prevalent in SjS, and the titers of
such ANAs are clinically important factors in diagnosing
the disease. To identify the presence of ANAs, sera col-
lected from C57BL/6.NOD-Aec1Aec2 mice treated at
either 6 or 14 weeks of age with rAAV2-IL27, rAAV2-
LacZ, or saline were tested for ANA reactivity by using
HEp-2 cells. Antibody titers were examined at dilutions
of 1:50, 1:100, 1:200, 1:400, and 1:800. As presented in
Figure 5A, sera from mice injected with rAAV2-IL27 at
either age showed comparatively weak or no nuclear
speckled antibody staining on the HEp-2 cells (shown at
a dilution of 1:400), whereas mice injected with AAV2-
LacZ or saline showed strong ANA staining, and this
was predominantly a nuclear speckled pattern. Quantifi-
cation of the nuclear speckled ANA titers clearly
revealed that, in mice treated at either age, the titers
present in rAAV2-IL27-treated mice were significantly
lower than in mice receiving injections of rAAV2-LacZ
vector or saline (Figure 5B, C). Thus, these results sug-
gest that increased levels of IL-27 in sera following
rAAV2-IL27 treatment directly affect production or pro-
files of autoantibodies (or both) in SjS mice.
Measurement of stimulated saliva flow rates
To compare SFRs in the C57BL/6.NOD-Aec1Aec2 mice
injected with rAAV2-IL27, rAAV2-LacZ, or saline,
pilocarpine/isopreterenol-stimulated saliva collections
were carried out every 4 weeks starting 8 weeks after
treatment, and each value equated to the average base-
line SFRs collected from the mice 1 week prior to begin-
ning treatment. As presented in Figure 6, mice treated
with either rAAV2-IL27 or rAAV2-LacZ at 6 weeks of
age exhibited a relatively rapid loss in SFRs. Mice in the
rAAV2-IL27 treatment group, however, showed a slight
recovery of SFRs with time, whereas mice in the
rAAV2-LacZ treatment group remained low. As
expected, mice receiving saline showed a progressive
loss in SFRs. These results suggest that the viral vectors
per se can influence the SFRs and that IL-27 may be
able to reverse the effect, albeit weakly.
In contrast to the above results, mice treated with either
rAAV2-IL27 or rAAV2-LacZ at 14 weeks of age exhibited
different responses to the treatments (Figure 6B): mice
receiving the rAAV-LacZ vector again exhibited a rapid
loss of SFR, whereas mice receiving the rAAV2-IL27 vec-
tor slowly showed minor improvements in their SFRs.
Mice receiving saline began showing a slower SFR after
about 8 weeks after treatment (or 22 weeks of age), consis-
tent with disease in this model. These results indicate that
IL-27 might impact the delayed recovery of SFRs when
treatment is done prior to the onset of disease and may
partially restore saliva secretion and glandular function at
a later stage.
Discussion
This study was undertaken to examine the effects of IL-27
gene therapy in SjS by using the C57BL/6.NOD-Aec1Aec2
mouse model of primary SjS. SjS is characterized by hypo-
salivation, autoantibodies in sera, and lymphocytic infiltra-
tion in the salivary glands. Previous findings also suggested
a role for the IL-23/TH17/IL-17A system in both patients
with SjS and animal models [33,34]. Therefore, we
hypothesized that IL-27 would have a therapeutic role in
treating SjS and show potential as a therapeutic for the
human disease. The results of the present study generally
support our hypothesis, showing that IL-27 overexpression
by the rAAV2-IL27 vector in C57BL/6.NOD-Aec1Aec2
mice increased saliva secretion and decreased ANA
Table 1 Quantification of lymphocytic infiltrates in the salivary glands of gene-delivered mouse groups
Disease stage Salivary glands Lacrimal glands
Treatment LF Meana LF Mean
Saline 5/6b (83%)c 2.3 ± 1.5 4/6 (67%) 2.8 ± 1.3
Pre-disease Lac-Z 7/7 (100%) 3.0 ± 2.4 6/7 (86%) 1.5 ± 0.7
IL-27 6/7 (86%) 4.3 ± 2.2 2/7d (29%) 2.0 ± 1.4
Clinical disease Lac-Z 7/7 (100%) 3.4 ± 2.4 4/7 (57%) 2.5 ± 1.0
IL-27 7/7 (100%) 3.4 ± 1.3 2/7 (29%) 4.5 ± 5.0
aMean lymphocytic foci (LF) score of each gland in mouse ± standard error of the mean per histological salivary gland section; bnumber of mice; cpercentage of
mice; dP < 0.05 by chi-squared test. IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; saline, saline-treated groups.
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formation despite a lack of differences in LF scores
between rAAV-IL27- and rAAV2-LacZ vector-treated
mice or saline-treated controls injected at 6 or 14 weeks of
age. Interestingly, rAAV2-IL27 treatment at the early clini-
cal disease stage appeared to show a better response than
treatment at a pre-disease stage.
The role of IL-27 has been studied, but the underlying
mechanism of IL-27 in autoimmune disease, specifically
SjS, is still unknown. Although IL-27 has pro-inflamma-
tory functions, which are embodied in activation of IFN-g
production from TH1 cells, many recent studies are
showing anti-inflammatory effects of IL-27 against
Figure 5 Nuclear speckled anti-nuclear antibody staining pattern profile. (A) Representative images of nuclear speckled anti-nuclear
antibody at a dilution of 1:400. Sera were collected in the pre-disease group at 6 weeks of age (before treatment) and 26 weeks of age or 20
weeks after treatment. In the clinical disease group, sera were collected at 14 weeks of age (before treatment) and 34 weeks of age or 20 weeks
after treatment. Images were captured at ×200 magnification with a Zeiss Axiovert 200 M microscope with a constant exposure of 0.3 seconds.
(B) Nuclear speckled titers in pre-disease treated mice. (C) Nuclear speckled titers in clinical disease treated mice. Three individuals in blinded
fashion determined autoantibody titers. Values are mean ± standard error of the mean (n = 7). *P < 0.05 rAAV2-IL27 group versus rAAV2-LacZ or
saline groups by one-way analysis-of-variance test. IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; Saline, saline-treated
groups. These symbols have no specific meanings because the legends on the x-axis defined them. However, if we must define these symbols,
are you ok with? Pre-disease stage: 6 weeks old mice (inverted triangle), saline-treated mice (circle), rAAV2-LacZ-treated mice (square), rAAV2-IL27-
treated mice (triangle). Clinical-disease stage: 14 weeks old mice (inverted triangle), saline-treated mice (circle), rAAV2-LacZ-treated mice (square),
rAAV2-IL27-treated mice (triangle).
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microorganisms and effector T cells, including TH17
cells. Recent studies have also shown that IL-27 is
involved in anti-inflammatory functions, especially inter-
fering with TNF-a or TH17 cells (or both) in autoim-
mune diseases, including multiple sclerosis, rheumatoid
arthritis, and systemic lupus erythematosus [35-38]. For
the potential therapeutic use of IL-27, previous in vivo
and in vitro studies have shown that IL-27 can be used as
an anti-tumor or anti-viral agent as well as a modulator
of autoimmunity [39-43]. IL-27-expressing vectors have
been shown to exhibit potent anti-tumor activity in
malignancies and metastatic tumors [9,44,45]. Therefore,
the present study, using IL-27 in a gene therapy protocol,
provides evidence that supports its potential effectiveness
in autoimmunity.
Our previous study, in which an adenoviral vector was
used, demonstrated that overexpression of IL-17 was cap-
able of recapitulating SjS phenotypes (lowered saliva secre-
tion and increased autoantibodies) in normal C57BL/6J
mice and, at the same time, showed differential immunolo-
gical or biological responses depending on the age of mice
at the time of treatment [34]. By inducing long-term
expression of IL-27 levels by using AAV2, our data showed
marked reductions in IL-17 cytokine levels in blood from
rAAV2-IL27-injected mice at two different phases of dis-
ease onset. Interestingly, there was delayed expression of
IL-27 in rAAV2-IL27-treated mice in the innate immune
phase in comparison with the expression in the adaptive
immune phase. This phenomenon could be attributed to
the age of the animals at the time of vector treatment.
A study by Bostick and colleagues [46] showed that AAV9
transduction by systemic delivery could be influenced by
the age of the animals. These authors found that AAVs
exhibited different transduction efficiencies and that adult
mice showed higher transduction efficiency than newborn
mice. Furthermore, other studies have implicated the ‘time
lag’ effect of AAV2-mediated transgene expression in var-
ious tissues, specifically myocardium [47-49]. Zincarelli and
colleagues [50] categorized AAV2 as a low-expression and
slow-onset virus along with AAV3, 4, and 5 among AAV
serotypes 1 to 9 after systemic injection in mice. Our study
also showed that the regulation of IL-17 could be directly
attributed to the overexpression of an IL-27 transgene, but
this could be the indirect systemic effect of IL-27 on other
regulatory cytokines and cell types. Although serum IL-27
is elevated at 8, 12, and 20 weeks after treatment in the
14-week treated group, serum IL-17 is markedly decreased
at 20 weeks after treatment. A number of factors can regu-
late the function of IL-17, especially TH1 cells releasing
IFN-g [4], which was increased in the rAAV2-IL27-treated
group (Figure 3). Also, independent roles of IL-27 subunits,
p28 and Ebi3, might be critical. A recent study by Stumho-
fer and colleagues [51] showed that IL-27 p28 alone binds
to gp130 as a pro-inflammatory signal antagonist.
Although gp130 is the subunit for IL-27 receptor with
WSX-1 (IL-27Ra), it is also a subunit for IL-6 receptor,
which is involved in TH17 cell differentiation. In addition,
Ebi3, a cytokine subunit of IL-35, is known for its suppres-
sion of TH17 cells [52]. Although rAAV2-IL27 vector
expresses both p28 and Ebi3, the possibility of independent
roles of p28 or Ebi3 could not be excluded here. Lastly,
other cell types (for instance, Tr-1) can regulate TH17 cells.
IL-27 has been shown to be able to stimulate Tr-1 cells,
which release IL-10 through STAT1 and STAT3 signaling
[53,54]. IL-10 is a cytokine that is known for its anti-
inflammatory function and the inhibitory effect on TH17
cells. However, recent studies using IL-27-overexpressing
transgenic mice showed an antagonist role of IL-27 on Treg
cells, another source for IL-10, through IL-2 modulation
[55]. Thus, IL-27 may have an effect on the balance of
Figure 6 Measurement of stimulated saliva flow rates (SFRs). One week prior to treatment, saliva was collected and measured to determine
the baseline SFRs. SFRs for each time point (8, 12, 16, and 20 post-gene delivery periods) were normalized against the baseline SFRs indicated as
zero (0) post-gene delivery periods. (A) Gene delivery in pre-disease stage at 6 weeks of age. (B) Gene delivery in clinical disease stage at 14
weeks of age. Values are mean ± standard error of the mean (n = 7). *P < 0.05 rAAV2-IL27 group versus rAAV2-LacZ or saline groups by one-way
analysis-of-variance test; **P < 0.01. IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; Saline, saline-treated groups.
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Tr-1 cells and Treg cells in the mouse or human system.
Therefore, multi-factorial regulation of IL-17 might have
contributed to the data in this study.
One unique feature of SjS is the formation of leukocyte
aggregates in the salivary and lacrimal glands, referred to
as either lymphoepithelial sialadenitis or LF [56,57]. At
times, these LF appear histologically to be germinal-like
centers and may be indicative of a more pronounced and
severe hypergammaglobulinemia [58]. Although LF and
LF scores are important criteria for clinical disease and
depict the level of lymphocytic infiltrations of the exocrine
glands, the scores often do not correlate with the severity
of disease [59,60]. Until recently, it was thought that sali-
vary gland-infiltrating leukocytes were mostly B lympho-
cytes and CD4+ TH1 cells. However, we recently reported
that LF contain significant numbers of CD4+ TH17 mem-
ory T cells plus IL-23-producing macrophages or dendritic
cells or both [33]. Although the present study shows no
difference in mean LF scores between IL-27-treated and
AAV2-LacZ vector- or saline-treated controls at the innate
or adaptive immune phase, other research has suggested a
poor correlation between this marker of disease and sali-
vary gland function [61].
As might be anticipated, only treatment with rAAV2-
IL27 at the clinical disease stage showed a stable and gra-
dual increase of SFRs compared with baseline SFRs over
the course of the experiment, whereas mice treated with
rAAV2-IL27 at the pre-disease stage showed slight recov-
ery of glandular function at 20 weeks after treatment.
These data are consistent with the serum IL-17 levels,
which were significantly downregulated at 20 weeks after
treatment for both studied groups. Further investigations
are needed to determine the underlying mechanism of
how IL-27 influences SFRs, although one possible mechan-
ism is the direct suppression of IL-17 in promoting the for-
mation of spontaneous germinal centers [62], thereby
dampening pathogenic autoantibody production [63]. This
concept appears to be supported in part by the altered
ANA profile and significant decrease in autoantibody titers
in rAAV2-IL27-treated mice.
Conclusions
We have provided a proof of concept that exogeneous IL-
27 is a potential factor for treating SjS. Although addi-
tional research in regard to gene delivery methods and
optimal disease time points are needed to further validate
the use of rAAV gene transfer, the use of mouse models
and systemic delivery of IL-27 provides a unique system
to study treatment of autoimmunity at the clinical disease
stage, which is applicable for treating patients with estab-
lished disease. Our results suggest that IL-27 gene ther-
apy could be an effective therapeutic strategy to reverse
the symptoms of SjS and should be further investigated.
Additional material
Additional file 1: Figure S1. Generation of IL-27 expressing serotype
2 adeno-associated viral vector (AAV2-IL27). A: Diagram of pTR-UF14
vector, which was given by Dr. Sergi Zolotuhkin (Department of
Pediatrics, University of Florida College of Medicine) for the back-bone
structure of rAAV2-IL27. B: Diagram of rAAV2-IL27. To fully recapitulate
the functionality of mouse IL-27 cytokine, a rAAV2-IL27 vector was
constructed by inserting the genes encoding the two subunits of IL-27
(Ebi3 and p28) into a pTR-UF14 vector.
Additional file 2: Figure S2. Relative expression of IL-27 p28 mRNA
in liver. To compare the transgene expression, livers in each group were
collected at the end of experiments (20-week of post delivery periods)
and total RNAs were extracted for cDNA synthesis. PCR primers were
designed using IDT’s PrimerQuestSM (Integrated DNA Technologies Inc.,
Coralville, IA, USA). Quantitative realtime PCR was performed using the
iCycler IQTM multi-color realtime PCR detection system (Bio-Rad
Laboratories). The Ct values obtained were normalized to those of 18S
ribosomal RNA. Level of IL-27 p28 mRNA in LacZ or IL-27 delivered
group were normalized against the mRNA level in saline group. (values
are mean ± SEM, *p < 0.05 rAAV2-IL27 group versus rAAV2-LacZ or saline
groups by one-way ANOVA test).
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